Literature DB >> 24488306

Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs.

Georgia McGaughey1, Christopher I Bayly, Christopher D Cox, John D Schreier, Michael J Breslin, Michael Bogusky, Steve Pitzenberger, Richard Ball, Paul J Coleman.   

Abstract

Dual Orexin Receptor Antagonists (DORA) bind to both the Orexin 1 and 2 receptors. High resolution crystal structures of the Orexin 1 and 2 receptors, both class A GPCRs, were not available at the time of this study, and thus, ligand-based analyses were invoked and successfully applied to the design of DORAs. Computational analysis, ligand based superposition, unbound small-molecule X-ray crystal structures and NMR analysis were utilized to understand the conformational preferences of key DORAs and excellent agreement between these orthogonal approaches was seen in the majority of compounds examined. The predominantly face-to-face (F2F) interaction observed between the distal aromatic rings was the core 3D shape motif in our design principle and was used in the development of compounds. A notable exception, however, was seen between computation and experiment for suvorexant where the molecule exhibits an extended conformation in the unbound small-molecule X-ray structure. Even taking into account solvation effects explicitly in our calculations, we nevertheless find support that the F2F conformation is the bioactive conformation. Using a dominant states approximation for the partition function, we made a comprehensive assessment of the free energies required to adopt both an extended and a F2F conformation of a number of DORAs. Interestingly, we find that only a F2F conformation is consistent with the activities reported.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488306      PMCID: PMC3927067          DOI: 10.1007/s10822-014-9710-x

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  15 in total

1.  Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding.

Authors:  Emanuele Perola; Paul S Charifson
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

2.  Ligand Entropy in Gas-Phase, Upon Solvation and Protein Complexation. Fast Estimation with Quasi-Newton Hessian.

Authors:  S Wlodek; A G Skillman; A Nicholls
Journal:  J Chem Theory Comput       Date:  2010-07-13       Impact factor: 6.006

3.  Conformational energy penalties of protein-bound ligands.

Authors:  J Boström; P O Norrby; T Liljefors
Journal:  J Comput Aided Mol Des       Date:  1998-07       Impact factor: 3.686

Review 4.  Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.

Authors:  Paul J Coleman; Christopher D Cox; Anthony J Roecker
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.

Authors:  Paul J Coleman; John D Schreier; Georgia B McGaughey; Michael J Bogusky; Christopher D Cox; George D Hartman; Richard G Ball; C Meacham Harrell; Duane R Reiss; Thomayant Prueksaritanont; Christopher J Winrow; John J Renger
Journal:  Bioorg Med Chem Lett       Date:  2010-02-08       Impact factor: 2.823

6.  Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

Authors:  Christopher D Cox; Michael J Breslin; David B Whitman; John D Schreier; Georgia B McGaughey; Michael J Bogusky; Anthony J Roecker; Swati P Mercer; Rodney A Bednar; Wei Lemaire; Joseph G Bruno; Duane R Reiss; C Meacham Harrell; Kathy L Murphy; Susan L Garson; Scott M Doran; Thomayant Prueksaritanont; Wayne B Anderson; Cuyue Tang; Shane Roller; Tamara D Cabalu; Donghui Cui; George D Hartman; Steven D Young; Ken S Koblan; Christopher J Winrow; John J Renger; Paul J Coleman
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

7.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

8.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

9.  Molecular shape and medicinal chemistry: a perspective.

Authors:  Anthony Nicholls; Georgia B McGaughey; Robert P Sheridan; Andrew C Good; Gregory Warren; Magali Mathieu; Steven W Muchmore; Scott P Brown; J Andrew Grant; James A Haigh; Neysa Nevins; Ajay N Jain; Brian Kelley
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

10.  Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database.

Authors:  Paul C D Hawkins; A Geoffrey Skillman; Gregory L Warren; Benjamin A Ellingson; Matthew T Stahl
Journal:  J Chem Inf Model       Date:  2010-04-26       Impact factor: 4.956

View more
  3 in total

1.  Structure-based development of a subtype-selective orexin 1 receptor antagonist.

Authors:  Jan Hellmann; Matthäus Drabek; Jie Yin; Jakub Gunera; Theresa Pröll; Frank Kraus; Christopher J Langmead; Harald Hübner; Dorothee Weikert; Peter Kolb; Daniel M Rosenbaum; Peter Gmeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

2.  Modeling & Informatics at Vertex Pharmaceuticals Incorporated: our philosophy for sustained impact.

Authors:  Georgia McGaughey; W Patrick Walters
Journal:  J Comput Aided Mol Des       Date:  2016-11-29       Impact factor: 3.686

3.  The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts.

Authors:  Jason M Uslaner; William J Herring; Paul J Coleman
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.